Literature DB >> 11101083

Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

W J Moretto1, L A Drohan, D F Nixon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11101083     DOI： 10.1097/00002030-200011100-00034

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  16 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.

Authors:  J D Steckbeck; H J Grieser; T Sturgeon; R Taber; A Chow; J Bruno; M Murphy-Corb; R C Montelaro; K S Cole
Journal:  J Med Primatol       Date:  2006-08       Impact factor: 0.667

4.  Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.

Authors:  Laurie E Harrington; Robbert van der Most Rv; J Lindsay Whitton; Rafi Ahmed
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.

Authors:  Philip M McKenna; Pyone Pyone Aye; Bernhard Dietzschold; David C Montefiori; Louis N Martin; Preston A Marx; Roger J Pomerantz; Andrew Lackner; Matthias J Schnell
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

6.  An adaptation of recombinant vaccinia-based ELISPOT and intracellular cytokine staining for a comparative measurement of cellular immune responses in HIV-1 and HIV-2 infections in West Africa.

Authors:  A Eshofonie; M Shim van der Loeff; H Whittle; A Jaye
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

7.  Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.

Authors:  John Schell; Nina F Rose; Nicole Fazo; Preston A Marx; Meredith Hunter; Elizabeth Ramsburg; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  Vaccine       Date:  2009-01-07       Impact factor: 3.641

Review 8.  Beyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues.

Authors:  B L Shacklett
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

9.  Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.

Authors:  Elizabeth Ramsburg; Nina F Rose; Preston A Marx; Megan Mefford; Douglas F Nixon; Walter J Moretto; David Montefiori; Patricia Earl; Bernard Moss; John K Rose
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.

Authors:  Jennifer A Slyker; Barbara L Lohman; Dorothy A Mbori-Ngacha; Marie Reilly; Edmund G-T Wee; Tao Dong; Andrew J McMichael; Sarah L Rowland-Jones; Tomas Hanke; Grace John-Stewart
Journal:  Vaccine       Date:  2005-02-19       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.